The high number of NRAS mutations in cutaneous melanoma did not allow the development of effective drugs: targeting directly NRAS remains a great challenge, and the target therapy for NRAS mutant melanoma is focused on MEK inhibitors. Here, NRAS is linked to cutaneous melanoma.